India, Dec. 4 -- Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility at Jarod, Vadodara. The EIR follows a GMP follow-up inspection conducted between August 25 and September 5, 2025, and classifies the site as Voluntary Action Indicated (VAI).
The inspection was carried out in connection with the Warning Letter issued by the USFDA on August 29, 2024.
The company said the update is being provided in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and has requested that the information be communicated to exchange members and investors.
Published by HT Digital Content ...